Ignite Creation Date:
2024-05-05 @ 10:46 PM
Last Modification Date:
2024-10-26 @ 10:23 AM
Study NCT ID:
NCT01180153
Status:
UNKNOWN
Last Update Posted:
2010-08-12
First Post:
2010-08-09
Brief Title:
Study of S-1 Oxaliplatin SOX for Biliary Tract Cancer BTC Ampullary Adenocarcinoma
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Study Overview
Official Title:
An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma
Status:
UNKNOWN
Status Verified Date:
2010-08
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate efficacy and safety of S-1 Oxaliplatin SOX regimen to patients with unresectable metastatic or locally advanced biliary tract or ampullary adenocarcinoma
Detailed Description:
To list in cases with unresectable metastatic or locally advanced biliary tract or ampullary adenocarcinoma that have not been treated beforeconfirm the efficacy and safety of combined S-1L-OHP regimen for the biliary tract or ampullary carcinoma providing evidence-based proof for the future treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None